PortfoliosLab logoPortfoliosLab logo
CI vs. MRK
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

CI vs. MRK - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in The Cigna Group (CI) and Merck & Co., Inc. (MRK). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, CI achieves a 2.54% return, which is significantly lower than MRK's 25.51% return. Over the past 10 years, CI has underperformed MRK with an annualized return of 9.54%, while MRK has yielded a comparatively higher 12.26% annualized return.


CI

1D
-2.99%
1M
-3.03%
6M
2.96%
YTD
2.54%
1Y
8.77%
3Y*
-0.02%
5Y*
5.92%
10Y*
9.54%
ALL TIME*
10.94%

MRK

1D
0.32%
1M
0.49%
6M
19.80%
YTD
25.51%
1Y
69.70%
3Y*
10.70%
5Y*
14.64%
10Y*
12.26%
ALL TIME*
12.54%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$460.57M$474.33M$477.27M
$997.19M$1.08B$1.21B

CI vs. MRK - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
CI
The Cigna Group
2.54%1.72%-6.27%-7.97%46.68%12.29%1.83%7.70%-6.46%52.29%
MRK
Merck & Co., Inc.
25.51%9.79%-6.26%1.01%49.42%1.75%-7.20%22.27%39.95%-1.49%

Correlation

The correlation between CI and MRK is 0.31, which is low. Their historical price movements had little consistent relationship.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.31

Correlation (3Y)
Balances recent behavior with more history.

0.27

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.32

Correlation (10Y)
Provides a long-term view across more market conditions.

0.32

Correlation (All Time)
Calculated using the full available price history since Mar 31, 1982

0.31

Fundamentals

Market Cap

CI:

$73.82B

MRK:

$321.62B

EPS

CI:

$24.16

MRK:

$3.59

PE Ratio

CI:

11.55

MRK:

36.23

PEG Ratio

CI:

0.67

MRK:

0.03

PS Ratio

CI:

0.26

MRK:

4.93

PB Ratio

CI:

1.73

MRK:

7.02

Total Revenue (TTM)

CI:

$282.38B

MRK:

$65.59B

Gross Profit (TTM)

CI:

$17.96B

MRK:

$49.79B

EBITDA (TTM)

CI:

$9.16B

MRK:

$22.69B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

CI vs. MRK — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

CI
CI Risk / Return Rank: 5151
Overall Rank
CI Sharpe Ratio Rank: 5454
Sharpe Ratio Rank
CI Sortino Ratio Rank: 4646
Sortino Ratio Rank
CI Omega Ratio Rank: 4747
Omega Ratio Rank
CI Calmar Ratio Rank: 5353
Calmar Ratio Rank
CI Martin Ratio Rank: 5454
Martin Ratio Rank

MRK
MRK Risk / Return Rank: 9696
Overall Rank
MRK Sharpe Ratio Rank: 9696
Sharpe Ratio Rank
MRK Sortino Ratio Rank: 9696
Sortino Ratio Rank
MRK Omega Ratio Rank: 9494
Omega Ratio Rank
MRK Calmar Ratio Rank: 9797
Calmar Ratio Rank
MRK Martin Ratio Rank: 9696
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

CI vs. MRK - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for The Cigna Group (CI) and Merck & Co., Inc. (MRK). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


CIMRKDifference
Sharpe ratioReturn per unit of total volatility

-2.43

Sortino ratioReturn per unit of downside risk

-3.24

Omega ratioGain probability vs. loss probability

1.07

1.44

-0.37

Calmar ratioReturn relative to maximum drawdown

0.31

6.39

-6.08

Martin ratioReturn relative to average drawdown

0.74

16.11

-15.37

CI vs. MRK - Sharpe Ratio Comparison

The current CI Sharpe Ratio is 0.21, which is lower than the MRK Sharpe Ratio of 2.64. The chart below compares the historical Sharpe Ratios of CI and MRK, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

CI vs. MRK - Drawdown Comparison

The maximum CI drawdown since its inception was -84.34%, which is greater than MRK's maximum drawdown of -68.61%. Use the drawdown chart below to compare losses from any high point for CI and MRK.


Loading charts...

Drawdown Indicators


CIMRKDifference

Max Drawdown

Largest peak-to-trough decline

-84.34%

-68.61%

-15.73%

Max Drawdown (1Y)

Largest decline over 1 year

-21.41%

-11.37%

-10.04%

Max Drawdown (3Y)

Largest decline over 3 years

-32.10%

-43.44%

+11.34%

Max Drawdown (5Y)

Largest decline over 5 years

-32.10%

-43.44%

+11.34%

Max Drawdown (10Y)

Largest decline over 10 years

-42.47%

-43.44%

+0.97%

Current Drawdown

Current decline from peak

-21.16%

-1.23%

-19.93%

Average Drawdown

Average peak-to-trough decline

-18.82%

-18.79%

-0.03%

Ulcer Index

Depth and duration of drawdowns from previous peaks

9.02%

4.50%

+4.52%

Volatility

CI vs. MRK - Volatility Comparison

The Cigna Group (CI) has a higher volatility of 10.65% compared to Merck & Co., Inc. (MRK) at 8.23%. This indicates that CI's price experiences larger fluctuations and is considered to be riskier than MRK based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


CIMRKDifference

Volatility (1M)

Calculated over the trailing 1-month period

10.65%

8.23%

+2.42%

Volatility (6M)

Calculated over the trailing 6-month period

20.43%

19.68%

+0.75%

Volatility (1Y)

Calculated over the trailing 1-year period

33.83%

27.87%

+5.96%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

28.73%

24.10%

+4.63%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

30.70%

23.13%

+7.57%

Dividends

CI vs. MRK - Dividend Comparison

CI's dividend yield for the trailing twelve months is around 2.20%, less than MRK's 2.58% yield.


PositionTTM20252024202320222021202020192018201720162015
CI
The Cigna Group
2.20%2.19%2.03%1.64%1.35%1.74%0.02%0.02%0.02%0.02%0.03%0.03%
MRK
Merck & Co., Inc.
2.58%3.12%3.14%2.72%2.52%3.41%3.03%2.48%2.60%3.36%3.14%3.43%

Financials

CI vs. MRK - Financials Comparison

This section allows you to compare key financial metrics between The Cigna Group and Merck & Co., Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

CI vs. MRK - Profitability Comparison

The chart below illustrates the profitability comparison between The Cigna Group and Merck & Co., Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

CI - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, The Cigna Group reported a gross profit of 0.00 and revenue of 71.67B. Therefore, the gross margin over that period was 0.0%.

MRK - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Merck & Co., Inc. reported a gross profit of 13.34B and revenue of 16.29B. Therefore, the gross margin over that period was 81.9%.

CI - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, The Cigna Group reported an operating income of 2.68B and revenue of 71.67B, resulting in an operating margin of 3.7%.

MRK - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Merck & Co., Inc. reported an operating income of -1.88B and revenue of 16.29B, resulting in an operating margin of -11.6%.

CI - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, The Cigna Group reported a net income of 1.66B and revenue of 71.67B, resulting in a net margin of 2.3%.

MRK - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Merck & Co., Inc. reported a net income of -4.24B and revenue of 16.29B, resulting in a net margin of -26.0%.


Frequently Asked Questions


CI and MRK have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CI has higher volatility (10.65%) compared to MRK (8.23%). In terms of maximum drawdown, CI dropped -84.34% vs MRK's -68.61%.

MRK currently has the higher Sharpe Ratio (2.64 vs 0.21), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for CI and MRK

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer